Amgen/AMGN

$278.50

-2.75%
-
1D1W1MYTD1YMAX

About Amgen

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness. It also offers TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase) and UPLIZNA (inebilizumab-cdon).

Ticker

AMGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Bradway

Employees

26,700

Headquarters

Thousand oaks, United States

Amgen Metrics

BasicAdvanced
$154.98B
Market cap
23.15
P/E ratio
$12.49
EPS
0.59
Beta
$8.52
Dividend rate
3.11%
Dividend yield

What the Analysts think about Amgen

Analyst Ratings

Majority rating from 29 analysts.
Buy

Price Targets

Average projection from 22 analysts.
10.45% upside
High $380.00
Low $170.00
$278.50
Current price
$307.59
Average price target

Amgen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
9.35% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$8.2B
18.73%
Net income
$767M
-55.66%
Profit margin
9.35%
-62.69%

Amgen Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.27%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$3.98
$5.00
$4.96
$4.71
-
Expected
$3.85
$4.49
$4.67
$4.61
$3.98
Surprise
3.45%
11.3%
6.16%
2.27%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Amgen stock

Buy or sell Amgen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing